Brand-name drug
Simponi price, strengths & recalls
Brand of golimumab (generic)
Pharmacies pay $6,450.56 for 0.5 mL of Simponi 100 mg/mL, 0.5 mL auto-injector this week, and from $6,450.56 to $6,488.62 across its 2 priced strengths and forms. Its official label last changed on November 4, 2026.
Brand- Fair cash price
- $7,428.64
- Strengths
- 2
- Makers
- 1
- Updated
- Nov 11
Simponi price by strength
What pharmacies pay for each strength and form this week (Nov 11, 2026), for the usual package. Choose one for its fair price, 52-week chart and makers.
| Strength and form | Per unit | Pharmacies pay | ||
|---|---|---|---|---|
| 100 mg/mL, 0.5 mL auto-injector Brand | $12,901.13 | $6,450.56 / 0.5 mL | ||
| 100 mg/mL, 1 mL auto-injector Brand | Not priced this week | |||
| 100 mg/mL, 0.5 mL prefilled syringe Brand | $12,977.24 | $6,488.62 / 0.5 mL | ||
Simponi vs generic golimumab
There is no generic version of Simponi on the market yet.
GenericGolimumab pricesSupply status: shortages & recalls
What people paid for Simponi
Bought it recently? Share the price, the pharmacy and how you paid - it's the most useful thing the next person can read.
Official label & what changed
These highlights do not include all the information needed to use SIMPONI safely and effectively. See full prescribing information for SIMPONI. SIMPONI ®(golimumab) injection, for subcutaneous use Initial U.S. Approval: 2009
WARNING: SERIOUS INFECTIONS AND MALIGNANCY
WARNING: SERIOUS INFECTIONS AND MALIGNANCY
See full prescribing information for complete boxed warning.
Serious infections leading to hospitalization or death including tuberculosis (TB), bacterial sepsis, invasive fungal (such as histoplasmosis), and other opportunistic infections have occurred in patients receiving SIMPONI (
5.1)
Discontinue SIMPONI if a patient develops a serious infection or sepsis (
5.1)
Perform test for latent TB; if positive, start treatment for TB prior to starting SIMPONI (
5.1)
Monitor all patients for active TB during treatment, even if initial latent TB test is negative (
5.1)
Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers, of which SIMPONI is a member (
5.2)
SERIOUS INFECTIONS
Patients treated with SIMPONI are at increased risk for developing serious infections that may lead to hospitalization or death
[see
Warnings and Precautions (5.1)]
. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids.
Discontinue SIMPONI if a patient develops a serious infection.
Reported infections with TNF blockers, of which SIMPONI is a member, include:
Active tuberculosis, including reactivation of latent tuberculosis. Patients with tuberculosis have frequently presented with disseminated or extrapulmonary disease. Test patients for latent tuberculosis before SIMPONI use and during therapy. Initiate treatment for latent TB prior to SIMPONI use.
Invasive fungal infections including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocystosis. Patients with histoplasmosis or other invasive fungal infections may present with disseminated, rather than localized, disease. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. Consider empiric antifungal therapy in patients at risk for invasive fungal infections who develop severe systemic illness.
Bacterial, viral, and other infections due to opportunistic pathogens, including Legionella and Listeria.
Consider the risks and benefits of treatment with SIMPONI prior to initiating therapy in patients with chronic or recurrent infection.
Monitor patients closely for the development of signs and symptoms of infection during and after treatment with SIMPONI, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy
[see
Warnings and Precautions (5.1)]
.
MALIGNANCY
Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers, of which SIMPONI is a member[seeWarnings and Precautions (5.2)]
.
Recent major changes (as listed on the label)
Indications and Usage (1.4) | 10/2025 |
Dosage and Administration (2.1, 2.3, 2.4) | 10/2025 |
Warnings and Precautions (5.11) | 10/2025 |
We check this label every day. When it changes, the sections that changed appear here, old text beside new.
We show the official text and what changed; we don't interpret it. Ask your pharmacist or prescriber what a change means for you.
Approval, patents & generics
- Application
- BLA125289 · Centocor Ortho Biotech Inc
- First approved
- April 24, 2009 (17 years ago)
- Latest approved change
- October 22, 2025
- Approved label
- PDF, Oct 23, 2025
- Generic makers
- None on the market
Simponi questions
How much does simponi cost without insurance?
Pharmacies pay about $6,450.56 for 0.5 mL of simponi 100 mg/mL, 0.5 mL auto-injector ($12,901.13 per mL). A fair cash price - that cost plus a 15% margin and a typical dispensing fee - is about $7,428.64. If you're quoted much more, check your quote and ask for the pharmacy's cash price.
Is there a generic for Simponi?
Yes: golimumab. Compare golimumab prices.
Is simponi in shortage?
No shortage is reported for simponi right now. We check the national shortage list every day.
Has simponi been recalled?
No recalls are on record for simponi.
When did the simponi label last change?
The official label was last updated on November 4, 2026 (version 44). See what changed.
Talk about simponi
No comments yet. Questions, tips, what worked for you - start the conversation.